Clinical Outcomes of Radiofrequency Catheter Ablation of VT in HCM
Authors, Journal, Affiliations, Type, DOI
- Authors: Jalaj Garg, Jakrin Kewcharoen, Kuldeep Shah, Mohit Turagam, Rahul Bhardwaj, Tahmeed Contractor, Ravi Mandapati, Dhanunjaya Lakkireddy
- Journal: Journal of Cardiovascular Electrophysiology 2023;34(1):219–224
- Affiliations: Loma Linda University Health (Loma Linda, CA); Beaumont Hospital, Oakland University William Beaumont School of Medicine (Royal Oak, MI); Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai (New York, NY); Kansas City Heart Rhythm Institute and Research Foundation (Kansas City, KS)
- Type: Systematic review and meta-analysis (6 studies, 68 patients)
- DOI: 10.1111/jce.15739
Overview
This systematic review pools six observational studies of radiofrequency ablation for ventricular tachycardia in hypertrophic cardiomyopathy, comprising 68 drug-refractory patients. Acute procedural success was 84.5%, freedom from recurrent ventricular tachycardia was 70.2% after the index procedure and 82.8% after the last ablation, and 27.9% of patients required multiple procedures. The apical-aneurysm subgroup had significantly better acute success and freedom from recurrence than the dilated-phase subgroup. The analysis is limited by the small, heterogeneous, retrospective source studies and by selection and operator-experience bias.
Keywords
Catheter ablation; Death; Hypertrophic cardiomyopathy; Ventricular tachycardia
Key Takeaways
Study design and population
- Systematic search of PubMed, EMBASE, SCOPUS, Google Scholar and ClinicalTrials.gov from inception to January 15, 2022; isolated case reports were excluded; PRISMA-guided; PROSPERO ID 309176.
- Six studies (three from the United States, three from Japan) with 68 patients who underwent radiofrequency ablation for drug-refractory hypertrophic cardiomyopathy–related ventricular tachycardia.
- Mean age 57.6 ± 13.3 years; 85% men; mean left ventricular ejection fraction 45.8% ± 15.4%; mean maximum septal wall thickness 17.4 ± 4.6 mm; 32.3% had an apical aneurysm.
- Sixty-one patients (89.7%) were on at least one antiarrhythmic drug, including amiodarone (69%), lidocaine (20%), mexiletine (17.5%), sotalol (17.5%), procainamide (5%) and disopyramide (2%).
- Ablation approach: combined epicardial-endocardial in 41.2%, endocardial only in 50%, and epicardial only in 9%; 79.4% used an open-irrigated catheter.
Acute and long-term outcomes
- Acute procedural success, defined as non-inducibility of clinical ventricular tachycardia, was 84.5% (95% CI 70.6–95.2%).
- Freedom from recurrent ventricular tachycardia after the index procedure was 70.2% (95% CI 51.9–86.2%) over a mean follow-up of 18.3 ± 11.7 months.
- Freedom from recurrent ventricular tachycardia after the last ablation was 82.8% (95% CI 57.0–99.2%).
- Twenty-seven and nine-tenths percent of patients had recurrent ventricular tachycardia requiring multiple ablations (median 1, IQR 1–3).
Apical aneurysm versus dilated-phase subgroup
- Acute procedural success was significantly higher in the apical-aneurysm subgroup than in the dilated-phase subgroup: 96.45% (95% CI 87.9–100; I² = 0%) versus 85% (95% CI 68.5–97.1; I² = 0%; P for interaction = 0.02).
- Freedom from recurrent ventricular tachycardia after the last ablation was also higher in the apical-aneurysm subgroup: 96.45% (95% CI 87.9–100; I² = 0%) versus 79.7% (95% CI 51.3–98.9; I² = 10%; P for interaction = 0.03).
- Freedom after the index procedure showed a trend in the same direction: 88.6% (95% CI 53.1–100; I² = 0%) versus 67.4% (95% CI 40.2–90.6; I² = 8%; P for interaction = 0.11).
Complications and mortality
- Eight adverse events occurred in 9.1% (95% CI 0–28.9%): two pericardial effusions requiring pericardiocentesis, two complete atrioventricular blocks (one transient, one permanent), one left anterior descending artery occlusion, one transient phrenic nerve palsy, and two groin haematomas.
- Two deaths occurred during follow-up, one from heart failure and one from sudden cardiac death (0.8%; 95% CI 0–5.8%).
Interpretation
- Pooled observational data support catheter ablation for drug-refractory hypertrophic cardiomyopathy–related ventricular tachycardia, with high acute success and durable freedom from recurrence in a substantial proportion.
- The apical-aneurysm phenotype responds better than dilated-phase hypertrophic cardiomyopathy, consistent with a scar-related, more accessible substrate.
- Combined epicardial-endocardial ablation may be considered, but the source studies are heterogeneous and the optimal strategy is not established.
Limitations of the document
- Small pooled sample (68 patients from 6 studies) with wide confidence intervals; the estimates are imprecise.
- Observational source studies with selection bias, operator-experience bias, and heterogeneity in phenotype, mapping strategy, ablation approach and follow-up.
- No randomised comparison with antiarrhythmic drugs or with a uniform ablation strategy.
- Subgroup analyses are post hoc and based on small numbers; the apical-aneurysm versus dilated-phase comparison is hypothesis-generating.
- Publication and language bias — only published studies were included; the search was not restricted by language but the included studies were from the United States and Japan.
- No patient-level data — the meta-analysis cannot adjust for confounders or identify predictors of recurrence.
Key Concepts Mentioned
- concepts/VT-in-HCM — the HCM-specific VT substrate and ablation outcomes
- concepts/VT-Ablation — the general procedural framework
- concepts/Epicardial-VT-Ablation — the epicardial approach
- entities/HCM — the underlying cardiomyopathy
- entities/ICD — device therapy
Key Entities Mentioned
- Hypertrophic cardiomyopathy
- Apical aneurysm
- Dilated-phase hypertrophic cardiomyopathy
Wiki Pages Updated
- Created:
wiki/sources/hcm-vt-ablation-meta-jce-2023.md - Updated:
wiki/concepts/VT-in-HCM.md - Updated:
wiki/entities/HCM.md - Updated:
wiki/concepts/HCM-Management.md - Updated:
wiki/concepts/VT-Ablation.md - Updated:
wiki/sourceindex.md - Updated:
wiki/wikiindex.md - Updated:
log.md